CWHM-1552 is an orally efficacious inhibitor of P. falciparum with IC50s of 51 nM and 53 nM for 3D7 and Dd2 strain, respectively[1].
IC50: 51 nM (3D7 strain) and 53 nM (Dd2 strain)[1]
CWHM-1552 (Compound (-)-32a) (orally; 3-30 mg/kg/day for 4 days) inhibits parasitemia at 99.9% at 30 mg/kg/day and 94% at 10 mg/kg/day[1]. CWHM-1552 (i.v. administration; 2 mg/kg/day for 48 hours) has respectable half-lives (2.7 h) and low clearance in mice[1]. CWHM-1552 has good pharmacokinetic properties and oral efficacy in a mouse model of malaria. CWHM-1552 has an in vivo ED90 of P. chabaudi ASS infected Mice[1]
